

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6864936

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HAZEL JOAN HUNT	05/20/2021
JEFFREY MARK DENER	05/19/2021
RECEIVING PARTY DATA	
Name:	CORCEPT THERAPEUTICS INCORPORATED
Street Address:	149 COMMONWEALTH DRIVE
City:	MENLO PARK
State/Country:	CALIFORNIA
Postal Code:	94025
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	17308380
PCT Number:	US2021030925
CORRESPONDENCE DATA	
Fax Number:	(617)542-2241
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 542-6000
Email:	IPDocketingBOS@mintz.com
Correspondent Name:	ALEXANDER R. TRIMBLE
Address Line 1:	ONE FINANCIAL CENTER
Address Line 2:	MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C.
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	052691-507001US 507001WO
NAME OF SUBMITTER:	ALEXANDER R. TRIMBLE
SIGNATURE:	/ALEXANDER R. TRIMBLE/
DATE SIGNED:	08/13/2021
Total Attachments: 3	
source=signed Assignment Corcept Inventors to Corcept 052691-507001US WO#page1.tif	
source=signed Assignment Corcept Inventors to Corcept 052691-507001US WO#page2.tif	
source=signed Assignment Corcept Inventors to Corcept 052691-507001US WO#page3.tif	

ASSIGNMENT
(Patent Application)

We, the undersigned, have invented certain inventions and improvements disclosed in a utility application titled

**POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID
RECEPTOR MODULATORS**

filed as U.S. Application No. 17/308,380 on May 5, 2021; and

filed as International Application No. PCT/US2021/030925 on May 5, 2021


For other good and valuable consideration, the receipt and sufficiency of which we acknowledge, we:


1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Corcept Therapeutics Incorporated**, having a principal place of business at 149 Commonwealth Drive, Menlo Park, California, 94025 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisional's, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this

paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and

- (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and the right to sue for and collect such damages and royalties for Assignee's own use.
2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
 3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
 4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us, as well as our heirs, legal representatives, and assigns.
 5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.

Inventors: Sign and date where indicated.


Signature:  Date: MAY 20, 2021
Hazel Joan Hunt

Signature:  Date: MAY 19, 2021
Jeffrey Mark Dener

ASSIGNMENT
POLYMORPHS OF PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR
MODULATORS
Attorney Docket No. 052691-507001US/WO
Page 3 of 3

DEED OF ACCEPTANCE

I (we), Corcept Therapeutics Incorporated, with offices at 149 Commonwealth Drive, Menlo Park, California, 94025, USA declare that I (we) accept the rights given in the attached assignment.

By: Shameek Ghose Date: 5/26/21
Name
Title 

VP of IP for Corcept Therapeutics Incorporated

111380235v.1